94 related articles for article (PubMed ID: 10083335)
1. Involvement of protein tyrosine phosphorylation in immunotoxin effects on T lymphocytes.
Hamawy MM; Tsuchida M; Fechner JH; Manthei E; Knechtle SJ
Transplant Proc; 1999; 31(1-2):785. PubMed ID: 10083335
[No Abstract] [Full Text] [Related]
2. Immunotoxin FN18-CRM9 induces stronger T cell signaling than unconjugated monoclonal antibody FN18.
Hamawy MM; Tsuchida M; Cho CS; Manthei ER; Fechner JH; Knechtle SJ
Transplantation; 2001 Aug; 72(3):496-503. PubMed ID: 11502982
[TBL] [Abstract][Full Text] [Related]
3. Effect of pre-existing anti-diphtheria toxin antibodies on T cell depletion levels following diphtheria toxin-based recombinant anti-monkey CD3 immunotoxin treatment.
Matar AJ; Pathiraja V; Wang Z; Duran-Struuck R; Gusha A; Crepeau R; Tasaki M; Sachs DH; Huang CA
Transpl Immunol; 2012 Aug; 27(1):52-4. PubMed ID: 22676970
[TBL] [Abstract][Full Text] [Related]
4. T-cell depletion and graft survival induced by anti-human CD3 immunotoxins in human CD3epsilon transgenic mice.
Weetall M; Digan ME; Hugo R; Mathew S; Hopf C; Tart-Risher N; Zhang J; Shi V; Fu F; Hammond-McKibben D; West S; Brack R; Brinkmann V; Bergman R; Neville D; Lake P
Transplantation; 2002 May; 73(10):1658-66. PubMed ID: 12042656
[TBL] [Abstract][Full Text] [Related]
5. Activation of T lymphocytes for adhesion and cytokine expression by toxin-conjugated anti-CD3 monoclonal antibodies.
Hamawy MM; Tsuchida M; Manthei ER; Dong Y; Fechner JE; Knechtle JS
Transplantation; 1999 Sep; 68(5):693-8. PubMed ID: 10507490
[TBL] [Abstract][Full Text] [Related]
6. The effect of anti-CD3-immunotoxin on T lymphocyte function in vitro.
Meng G; Jiang Y; Hubbard W; Thomas JM
Transpl Immunol; 1998 Mar; 6(1):53-9. PubMed ID: 9640629
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms of tolerance induced by an immunotoxin against CD3 epsilon in a rhesus kidney allograft model.
Fechner JH; Vargo DJ; Geissler EK; Wang J; Neville DM; Knechtle SJ
Transplant Proc; 1997; 29(1-2):1158. PubMed ID: 9123249
[No Abstract] [Full Text] [Related]
8. Immunotoxin-treated rhesus monkeys: a model for renal allograft chronic rejection.
Torrealba JR; Fernandez LA; Kanmaz T; Oberley TD; Schultz JM; Brunner KG; Peters D; Fechner JH; Dong Y; Hu H; Hamawy MM; Knechtle SJ
Transplantation; 2003 Aug; 76(3):524-30. PubMed ID: 12923438
[TBL] [Abstract][Full Text] [Related]
9. A new reagent for the induction of T-cell depletion, anti-CD3-CRM9.
Neville DM; Scharff J; Hu HZ; Rigaut K; Shiloach J; Slingerland W; Jonker M
J Immunother Emphasis Tumor Immunol; 1996 Mar; 19(2):85-92. PubMed ID: 8732691
[TBL] [Abstract][Full Text] [Related]
10. Reversal of acute allograft rejection using immunotoxin.
Knechtle SJ; Fechner JH; Stavrou S; Neville DM; Dong Y; Hong X; Tsuchida M; Hamawy MM
Transplant Proc; 1998 Aug; 30(5):2150-1. PubMed ID: 9723422
[No Abstract] [Full Text] [Related]
11. Improvement of a recombinant anti-monkey anti-CD3 diphtheria toxin based immunotoxin by yeast display affinity maturation of the scFv.
Wang Z; Kim GB; Woo JH; Liu YY; Mathias A; Stavrou S; Neville DM
Bioconjug Chem; 2007; 18(3):947-55. PubMed ID: 17352456
[TBL] [Abstract][Full Text] [Related]
12. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis.
Gottlieb SL; Gilleaudeau P; Johnson R; Estes L; Woodworth TG; Gottlieb AB; Krueger JG
Nat Med; 1995 May; 1(5):442-7. PubMed ID: 7585092
[TBL] [Abstract][Full Text] [Related]
13. Dosing optimization of CCR4 immunotoxin for improved depletion of CCR4
Wang Z; Louras NJ; Lellouch AG; Pratts SG; Zhang H; Wang H; Huang CA; Cetrulo CL; Madsen JC; Sachs DH; Wang Z
Mol Oncol; 2018 Aug; 12(8):1374-1382. PubMed ID: 29873181
[TBL] [Abstract][Full Text] [Related]
14. Split tolerance induced by immunotoxin in a rhesus kidney allograft model.
Fechner JH; Vargo DJ; Geissler EK; Graeb C; Wang J; Hanaway MJ; Watkins DI; Piekarczyk M; Neville DM; Knechtle SJ
Transplantation; 1997 May; 63(9):1339-45. PubMed ID: 9158030
[TBL] [Abstract][Full Text] [Related]
15. Sequential effects of interleukin 2-diphtheria toxin fusion protein on T-cell activation.
Walz G; Zanker B; Brand K; Waters C; Genbauffe F; Zeldis JB; Murphy JR; Strom TB
Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9485-8. PubMed ID: 2594781
[TBL] [Abstract][Full Text] [Related]
16. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity.
Greenfield L; Johnson VG; Youle RJ
Science; 1987 Oct; 238(4826):536-9. PubMed ID: 3498987
[TBL] [Abstract][Full Text] [Related]
17. Involvement of CD2 and CD3 in galectin-1 induced signaling in human Jurkat T-cells.
Walzel H; Blach M; Hirabayashi J; Kasai KI; Brock J
Glycobiology; 2000 Feb; 10(2):131-40. PubMed ID: 10642604
[TBL] [Abstract][Full Text] [Related]
18. Toward preclinical studies with anti-CD86 immunotoxin.
Otten HG; Ossevoort M; Vooijs WC; van der Gouw AP; de Boer M; de Gast GC
Transplant Proc; 1999; 31(1-2):1236. PubMed ID: 10083551
[No Abstract] [Full Text] [Related]
19. Phenotypic and functional analysis of T-cell recovery after anti-CD3 immunotoxin treatment for tolerance induction in rhesus macaques.
Hubbard WJ; Moore JK; Contreras JL; Smyth CA; Chen ZW; Lobashevsky AL; Nagata K; Neville DM; Thomas JM
Hum Immunol; 2001 May; 62(5):479-87. PubMed ID: 11334671
[TBL] [Abstract][Full Text] [Related]
20. Interleukin-2 fusion protein (DAB389IL-2) selectively targets activated human peripheral blood and lamina propria lymphocytes.
Bousvaros A; Stevens AC; Strom TB; Murphy J; Lamont JT
Dig Dis Sci; 1997 Jul; 42(7):1542-8. PubMed ID: 9246061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
